« Return to News | Clinical Intelligence

Merck pulls out of Portola collaboration

Tuesday, March 29, 2011 12:49 PM

Merck has returned global rights for the investigational clotbuster betrixaban to California-based Portola Pharmaceuticals, according to PharmaTimes.

Betrixaban is an oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation. In July 2009, Merck and Portola announced a collaboration for the drug that could have been worth $470 million plus royalties, and Merck made an upfront payment of $50 million.

Betrixaban completed the phase II EXPLORE-Xa trial in which it showed dose-dependent clinical activity with similar or lower rates of bleeding compared to warfarin. Luciano Rossetti, head of global scientific strategy at Merck, said, "working closely with our Portola collaborators we have advanced betrixaban to this phase III-ready stage."

However, the rights have been returned "as part of an ongoing prioritization of our late-stage pipeline," though he stressed that Merck "remains committed to delivering medicines for cardiovascular disease."

Portola CEO William Lis said regaining the rights "represents a transformational opportunity" for the firm. "We will work with our academic partners on options for an independent development plan to bring betrixaban to the market and intend to discuss these options with the FDA in the near future."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.